IXICO plc

LSE IXI.L

IXICO plc Capital Expenditure for the year ending September 30, 2024: USD -629.90 K

IXICO plc Capital Expenditure is USD -629.90 K for the year ending September 30, 2024, a 73.70% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • IXICO plc Capital Expenditure for the year ending September 30, 2023 was USD -2.40 M, a 4.36% change year over year.
  • IXICO plc Capital Expenditure for the year ending September 30, 2022 was USD -2.50 M, a 13.69% change year over year.
  • IXICO plc Capital Expenditure for the year ending September 30, 2021 was USD -2.90 M, a -96.78% change year over year.
  • IXICO plc Capital Expenditure for the year ending September 30, 2020 was USD -1.47 M, a -453.05% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
Loading...
SV Wall Street
LSE: IXI.L

IXICO plc

CEO Mr. Bram Goorden M.Sc.
IPO Date April 25, 1996
Location United Kingdom
Headquarters Griffin Court
Employees 89
Sector Healthcare
Industries
Description

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

Similar companies

1783.HK

Golden Ponder Holdings Limited

USD 0.91

-0.19%

StockViz Staff

February 6, 2025

Any question? Send us an email